Your browser doesn't support javascript.
loading
Lean/normal-weight metabolic dysfunction-associated fatty liver disease is a risk factor for reflux esophagitis.
Fukunaga, Shuhei; Nakano, Dan; Tsutsumi, Tsubasa; Kawaguchi, Takumi; Eslam, Mohammed; Yoshinaga, Shinobu; Abe, Hirohiko; Nouno, Ryuichi; Joh, Seiya; Mitsuyama, Keiichi; George, Jacob; Torimura, Takuji.
Afiliação
  • Fukunaga S; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
  • Nakano D; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
  • Tsutsumi T; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
  • Kawaguchi T; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
  • Eslam M; Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia.
  • Yoshinaga S; Medical Examination Section, Medical Examination Part Facilities, Public Utility Foundation Saga Prefectural Health Promotion Foundation, Saga, Japan.
  • Abe H; Kumamoto Central Hospital, Kikuchi, Japan.
  • Nouno R; Kumamoto Central Hospital, Kikuchi, Japan.
  • Joh S; Terao Hospital, Kumamoto, Japan.
  • Mitsuyama K; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
  • George J; Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, New South Wales, Australia.
  • Torimura T; Department of Medicine, Division of Gastroenterology, Kurume University School of Medicine, Kurume, Japan.
Hepatol Res ; 52(8): 699-711, 2022 Aug.
Article em En | MEDLINE | ID: mdl-35585481
ABSTRACT

AIM:

Reflux esophagitis is associated with metabolic dysfunction. Recently, fatty liver has been redefined as metabolic dysfunction-associated fatty liver disease (MAFLD). We investigated the impact of MAFLD and its subtypes on the incidence of reflux esophagitis.

METHODS:

This multicenter, observational cohort study enrolled 9100 consecutive health-check examinees who underwent esophagogastroduodenoscopy and ultrasonography. All patients were classified into the MAFLD or non-MAFLD group. Based on the Asian cut-off value for body mass index (BMI), the MAFLD group was further classified into the lean/normal-weight (BMI <23 kg/m2 ) and overweight/obese (BMI ≥23 kg/m2 ) subgroups. The impact of MAFLD and its subtypes on the cumulative incidence of reflux esophagitis was evaluated using multivariable Cox proportional hazards regression analysis.

RESULTS:

MAFLD was diagnosed in 26.5% (2416/9100) of patients. Multivariable Cox proportional hazards regression analysis indicated that MAFLD (hazard ratio [HR] 1.2183; 95% confidence interval [CI] 1.0954-1.3550; p = 0.0003), hiatal hernia, and aging were independent risk factors for reflux esophagitis. Stratification analysis indicated that cumulative incidence of reflux esophagitis among patients with MAFLD was significantly higher in the lean/normal-weight than in the overweight/obese group (HR 1.3274; 95% CI 1.0043-1.7547; p = 0.0466). Among various metabolic factors, visceral adiposity was the only independent metabolic risk factor for reflux esophagitis (HR 2.8331; 95% CI 1.0201-7.8691; p = 0.0457) in the lean/normal-weight MAFLD group.

CONCLUSIONS:

MAFLD, in particular lean/normal-weight MAFLD, is independent risk factor for reflux esophagitis. Furthermore, visceral adiposity was identified as the most strong metabolic risk factor for reflux esophagitis in lean/normal-weight patients with MAFLD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hepatol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Hepatol Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Japão